Stock Events

Stock Events

CRISPR Therapeutics 

$48.44
1866
-$3.29-6.36%Friday 07:34

Statistics

Day High
48.6
Day Low
47.82
52W High
62
52W Low
47.02
Volume
22,015
Avg. Volume
-
Mkt Cap
4.68B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 16Expected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
-1.37
-1.23
-1.08
-0.94
Expected EPS
-1.174242
Actual EPS
N/A

Financials

-16,569.77%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.51MRevenue
-581.6MNet Income

Analyst Ratings

$72.86Average Price Target
The highest estimate is ⁦90.00⁩.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
43%
Hold
57%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRSP.BOATS. It's not an investment recommendation.
NVIDIA
399
NVDA
Tesla
396
TSLA
Amazon
362
AMZN
Microsoft
355
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine focuses on genome editing using CRISPR technology, directly competing in the gene editing space.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, making it a direct competitor.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics uses base editing, a form of gene editing that competes with CRISPR's approach to therapeutics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals works on RNAi therapeutics, which, while a different technology, competes in the genetic disease treatment market.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals collaborates with CRISPR Therapeutics on certain projects but also competes in developing other genetic therapies independently.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops gene therapies for rare genetic disorders, competing for similar patient populations.
PTC Therapeutics
PTCT
Mkt Cap5.01B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for genetic disorders, competing in the broader market for genetic therapies.
Regenxbio
RGNX
Mkt Cap475.29M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, competing in the gene therapy space with a focus on adeno-associated virus (AAV) vectors.

About

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Show More
CEO
ISIN
CH0334081137

Listings

MX
MX
CRSPN.MX
STU
DE
1CG.STU
MU
DE
1CG.MU
F
DE
1CG.F

0 Comments

Share your thoughts

FAQs

What is CRISPR Therapeutics stock price today?▼
The current price of CRSP.BOATS is $48.44 USD — it has decreased by -6.36% in the past 24 hours. Watch CRISPR Therapeutics stock price performance more closely on the chart.
What is CRISPR Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange CRISPR Therapeutics stocks are traded under the ticker CRSP.BOATS.
What is CRISPR Therapeutics market cap?▼
Today CRISPR Therapeutics has the market capitalization of 4.68B
When is the next CRISPR Therapeutics earnings date?▼
CRISPR Therapeutics is going to release the next earnings report on February 16, 2027.
What were CRISPR Therapeutics earnings last quarter?▼
CRSP.BOATS earnings for the last quarter are -1.15 USD per share, whereas the estimation was -1.04 USD resulting in a -10.92% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CRISPR Therapeutics revenue for the last year?▼
CRISPR Therapeutics revenue for the last year amounts to 3.51M USD.
What is CRISPR Therapeutics net income for the last year?▼
CRSP.BOATS net income for the last year is -581.6M USD.
In which sector is CRISPR Therapeutics located?▼
CRISPR Therapeutics operates in the Other sector.
When did CRISPR Therapeutics complete a stock split?▼
CRISPR Therapeutics has not had any recent stock splits.